Market Overview

UPDATE: China International Capital Reiterates Buy Rating, Raises PT for Mindray

Related MR
Benzinga's M&A Chatter for Thursday September 10, 2015
Mindray Announces Receipt of Revised Non-binding Proposal to Acquire the Company at $27 per ADS or $27 per Ordinary Share

In a report published earlier today, China International Capital Corporation Limited reiterated its Buy rating for Mindray Medical International Limited (NYSE: MR) and raised its price target from $31.50 to $35.00.

CICC went on to say “In 1Q, Mindray acquired a controlling stake of Hangzhou Optcla Medical Instrument, a domestic medical endoscope producer that specializes in rigid endoscopes and related surgical instrument and consumables. The new addition will allow Mindray to tap into the fast growing minimally invasive and digitalized operating equipment market. The Chinese and international endoscopes market sizes were estimated to be ~US$240mn in 2010 (CAGR close to 15%) and ~US$2.6bn in 2011 (CAGR of 5%).”

Mindray Medical International Limited closed yesterday at $31.60.

Latest Ratings for MR

Jun 2015JMP SecuritiesUpgradesUnderperformMarket Perform
Mar 2015Credit SuisseDowngradesNeutralUnderperform
Mar 2015JMP SecuritiesMaintainsMarket Underperform

View More Analyst Ratings for MR
View the Latest Analyst Ratings

Posted-In: China International Capital Corp.Analyst Color Price Target Reiteration Analyst Ratings


Related Articles (MR)

View Comments and Join the Discussion!

Get Benzinga's Newsletters